What is Cryosa?
Cryosa is a specialized medical device innovator dedicated to addressing the global burden of sleep apnea. Unlike traditional therapeutic modalities that often suffer from low patient adherence, Cryosa is pioneering minimally invasive, patient-centric devices designed to integrate seamlessly into daily life. By focusing on hardware that eliminates the need for daily compliance, the company is effectively disrupting the standard of care in respiratory health.
The company's market position is bolstered by its commitment to engineering excellence and clinical efficacy. By targeting the root causes of sleep apnea through advanced, low-friction interventions, Cryosa is well-positioned to capture significant market share in the rapidly expanding sleep medicine landscape. Their approach represents a paradigm shift from legacy CPAP-based treatments toward more sustainable, long-term patient outcomes.
How much funding has Cryosa raised?
Cryosa has raised a total of $35.7M across 3 funding rounds:
Series A
$8.3M
Series B
$21.5M
Stock/Share Issuance
$6M
Series A (2020): $8.3M with participation from HOYA Corporation and Santé Ventures
Series B (2021): $21.5M led by Solas BioVentures, HOYA, and Santé Ventures
Stock/Share Issuance (2025): $6M, investors not publicly disclosed
Key Investors in Cryosa
Solas BioVentures
Solas BioVentures is a venture capital firm based in Chattanooga, Tennessee, that specializes in early-stage investments in the life sciences sector, including biopharmaceuticals, medical devices, and digital health.
Santé Ventures
Santé is a privately held investment firm that focuses on innovative healthcare and technology companies, managing over $1 billion in capital with a focus on Biotech, Medtech, and Healthtech sectors.
HOYA Corporation
HOYA Corporation is a global technology and medtech company that provides innovative solutions in healthcare and information technology, often acting as a strategic partner for medical device development.
What's next for Cryosa?
With the recent influx of capital, Cryosa is poised to scale its operational capabilities and advance its core product pipeline. The strategic focus will likely shift toward finalizing clinical validation and navigating regulatory pathways to ensure broad market access. Given the company's history of securing backing from specialized life sciences investors, the next phase of growth will likely involve expanding its commercial footprint and refining its manufacturing processes to meet anticipated demand.
Investors and industry stakeholders will be closely monitoring the company's progress as it moves toward commercialization. The combination of a strong balance sheet and a clear technological advantage positions Cryosa to become a dominant player in the Medtech space, potentially setting a new benchmark for how sleep apnea is managed on a global scale.
